AzTrials
AzTrials

Coronary Artery DiseaseNCT06543641

Evaluation of Long Coronary Artery Stents With Third-generation Dual-source Computed Tomography Angiography

A study testing Coronary computed tomography angiography and Invasive coronary angiography in people with Coronary Artery Disease and Chronic Total Occlusion of Coronary Artery, run by Lauri Mansikkaniemi at 1 site in Finland.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The goal of this clinical trial is to assess third-generation dual-source coronary computed tomography angiography (CCTA) performance in the evaluation of long coronary stents in patients with coronary artery chronic total occlusions. Read more about this study

Who is it for?
Ages Up to 75 years
What is being tested?
Coronary computed tomography angiography and Invasive coronary angiography
Could I receive a placebo?
No, everyone receives an active treatment
How many people
45 participants
Where
1 siteFinland
Study dates
16 Jan 2023to 8 Jun 2024
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Up to 75 years
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Who may be able to join

  • Surviving patients with a CTO PCI minimum of four years prior to the study date
  • Successful CTO PCI with a drug-eluting stent
  • Primary procedure minimum of four years prior to study date
  • CTO stent length ≥ 38 mm in right coronary artery (RCA) and left anterior descending (LAD) coronary artery
  • CTO stent length ≥ 30 mm in left circumflex coronary artery (LCX). The definition is clinical.
  • Age at primary procedure ≤ 75 years
  • Communication in English, Finnish or Swedish

Who cannot join

  • Malignancy with poor prognosis or ongoing diagnostics
  • Significantly impaired performance in daily activities
  • Significant psychiatric disorder
  • Active alcohol or drug abuse
  • Memory disorder or other cognitive impairment
  • Primary procedure in-stent CTO PCI
Show all 9Show fewer
  • Target vessel revascularisation or CABG after the primary - procedure
  • Glomerular filtration rate ≤40 ml/min
  • ICA or CCTA less than six months prior to the study date

Trial locations and contacts

1 site in 1 country.

Finland1 site
  • Helsinki University Central Hospital

    Helsinki, Uusimaa, 00290

Other trials in Finland

About this study

The goal of this clinical trial is to assess third-generation dual-source coronary computed tomography angiography (CCTA) performance in the evaluation of long coronary stents in patients with coronary artery chronic total occlusions. The main questions it aims to answer are:

  • Can patency of long coronary artery stents be assessed with third generation CCTA?
  • What are the factors affecting the assessability?
  • What is the radiation exposure of third generation CCTA?
Read the detailed description

This prospective study complied with the Declaration of Helsinki and was approved by the ethics committee of Helsinki University Central Hospital. All patients gave a written informed consent prior to the beginning of the study.

Patient selection A registry that included chronic total occlusion (CTO) patients with stable coronary artery disease treated for CTO with percutaneous coronary angioplasty (CTO PCI) in Helsinki University Central Hospital starting from 2014 was used for this study. The study population included consecutive, prospectively recruited patients from 2014 to 2019. All patients meeting the study criteria were included in the study.

Definition Segments 5 mm proximal and 5 mm distal to the stent were considered as part of the stent for in-stent restenosis (ISR) evaluation, as proposed by the Academic Research Consortium and were included in CCTA performance analyses. Long CTO stents consisted of one or more coronary artery stents with possible combination of different stent types. The combined stent length was reported without possible overlap for multiple stents. The diameter of the largest stent or post-dilation balloon was reported. Based on previous CT studies and guidelines radiological ISR in CCTA was defined as luminal narrowing of ≥ 50% in the long CTO stent. CCTA result was considered negative if ISR was ruled out and positive if ISR was detected or if the result was inconclusive. Therefore, two groups defined by the CCTA result were formed. In patient-based analyses patients with two long CTO stents of which at least one was a CCTA positive stent were considered as CCTA positive. In native coronary arteries less than 25% was considered minimal, 25-49% mild, 50-69% moderate and 70-99% severe stenosis and 100% as an occlusion. Assessment of stenosis was based on direct visualisation. The study's experienced cardiac radiologist with over 15 years of experience was blinded for symptomatic data, stent type and stent quantity. The target vessel of implanted coronary artery stents was provided.

All patients underwent third-generation dual-source CCTA. In CCTA a non-contrast calcium score using standard 120 kilovolt (kV) acquisition and 3 mm slice thickness was obtained. Stented segments were manually subtracted from the score. Second, third-generation dual-source CCTA (Somatom Force, Siemens) was performed. Prospective ECG-triggering was applied regular heart rate < 70/min and/or in the case of previous stent implantation of right coronary artery (RCA) to avoid motion artefacts and FLASH- mode if the heart rate was regular and < 60/min. If the presenting heart rate was > 70/min, metoprolol 5-15 mg was administered intravenously. For patients with higher heart rates (> 70/min) prospective ECG-gating and widening of the acquisition window (padding) were used. Sublingual nitroglycerin was administered before scanning. A tube voltage of 100 kV, rotation time of 0.25 s, temporal resolution of 66 ms, collimation of 2 x 192 x 0.6 mm and pitch of 3.2 were used. Approximately 50 ml of contrast medium containing 350 mg/ml of iodine (Omnipaque 350, GE Healthcare) was injected intravenously at a flow rate of 5-5.7 ml/s, followed by a 47 ml saline solute. Axial images were reconstructed with 0.6 mm slice and evaluated using multiplanar reformation. Bv40 kernel, Advanced Modeled Iterative Reconstruction 3 (ADMIRE 3) and Iterative metal artefact reduction (iMAR) were utilised.

Clinical information and CCTA results were assessed by the interventional cardiologists and the following patients were offered invasive coronary angiography (ICA):

  1. Patients with a positive result in a long CTO stent
  2. Patients with a positive result in a non-CTO stent
  3. Patients with ≥ 50% stenosis or an inconclusive finding in any native coronary artery in patients with anginal symptoms.

Physiological evaluation (fractional flow reserve) and intravascular imaging (intravascular ultrasound, optical coherence tomography) were performed in ICA by the decision of the interventional cardiologist. Any incidental findings were evaluated separately.

Radiation exposures of CCTA and ICA were reported in dose length product (DLP, milligray*cm) and dose area product (DAP, gray*cm2), respectively. DLP was converted to an effective dose (mSv) with a conversion factor of k = 0.014 and DAP with a conversion factor of k = 0.29. The effective doses were compare between patients who received both examinations.

Patients' symptoms were evaluated with the validated Seattle Angina Questionnaire 7 (SAQ7) via a single phone interview. Dyspnea was considered as an anginal symptom. All patients with SAQ7 Anginal Frequency score 100 were considered asymptomatic.

At the CTO PCI, optimal medical therapy was prescribed to all patients.

Stent- and patient-related characteristics examined in the study:

Age (years), body mass index (kg/m2), sex, smoking history, medical conditions at CTO PCI (diabetes, insulin required diabetes, heart failure, peripheral artery disease, dyslipidemia, hypertension, pulmonary disease, chronic kidney disease, atrial fibrillation, cardiac pacemaker, prior myocardial infarction, prior stroke, prior PCI, prior CABG), double-CTO (two treated CTO:s in one procedure), coronary artery dominance (RCA, left circumflex coronary artery (LCX), balanced)), a non-CTO stent implanted in the CTO PCI procedure, clinical presentation (stable angina pectoris or acute coronary syndrome), CCTA Agatston calcium score, stented vessel (RCA, left anterior descending artery (LAD), LCX), Japanese-CTO score (objective index of CTO procedure difficulty), long CTO stent parameters (number of consecutive stents, total stent length (mm), stent length in lesions stented with a single stent (mm), stent length in lesions stented with multiple stents (mm), stent diameter (mm)), duration of the follow-up since stent implantation (years).

The values are presented as medians and IQRs or n (%), as appropriate. The stent lengths are presented as medians and ranges (minimum-maximum).

Statistical analysis Descriptive statistics were reported with median and interquartile range (IQR) for continuous variables, and with frequency (%) for categorical variables. The demographic variables of the CCTA-positive group were compared to the corresponding variables of the CCTA-negative group. Categorical variables were analysed with Fisher's exact test or Pearson's chi-square test, and continuous or ordinal variables with Mann-Whitney U test. The alpha level was 0.05. CCTA performance in evaluating the patency of CTO stents was analysed with sensitivity, specificity, negative predictive value (NPV) and positive predictive value (PPV) in patients receiving both CCTA and ICA. ICA was the reference standard. All the statistical analyses were performed using SPSS version 28 (IBM).

Being tested
Coronary computed tomography angiography, Invasive coronary angiography
Keywords
coronary artery disease, drug-eluting stent, percutaneous coronary intervention, coronary computed tomography angiography
Medical subject headings
Coronary Artery Disease

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Coronary computed tomography angiographyDiagnostic test

    Also called CCTA

    All patients received coronary computed tomography angiography.

  • Invasive coronary angiographyDiagnostic test

    Also called ICA

    According to the study criteria some of the patients received confirmation imaging with invasive coronary angiography.

Study groups in NCT06543641
Study groupRoleWhat they receive
Study populationOtherAll patients included in the study.
Receives: Diagnostic Test: Coronary computed tomography angiography; Diagnostic Test: Invasive coronary angiography

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Stent patency assesment with third-generation dual-source CCTA

    Assessability of stent patency with third-generation dual-source CCTA in long coronary artery chronic total occlusion stents. CCTA results were divided into three categories: 1) negative (<50% stent luminal narrowing), 2) ISR (> 50% stent luminal narrowing) or 3) inconclusive (CCTA was not able to define the degree of stent luminal narrowing). Patients with ISR or inconclusive result were considered as CCTA positive. Confirmation imaging was conducted with ICA, if necessary. Positive predictive value, negative predictive value, sensitivity and specificity were calculated.

    Measured: up to 7.3 months (maximum time between CCTA and ICA)

Secondary outcomes (2)
  1. To determine significant differences in distribution of patient- and lesion-related characteristics in third-generation dual-source CCTA negative versus positive patient groups.

    Patient-related characteristics assessed: age, body mass index, sex, smoking history, medical conditions at CTO PCI (diabetes, insulin required diabetes, heart failure, peripheral artery disease, dyslipidemia, hypertension, pulmonary disease, chronic kidney disease, atrial fibrillation, cardiac pacemaker, prior myocardial infarction, prior stroke, prior PCI, prior CABG), double-CTO (two treated CTO:s in one procedure), coronary artery dominance (RCA, LCX or balanced), a non-CTO stent implanted in the CTO PCI procedure, clinical presentation (stable or acute), CCTA Agatston calcium score.

    Lesion-related characteristics assessed: stented vessel (RCA, LAD, LCX), Japanese-CTO score (objective index of CTO procedure difficulty), long CTO stent parameters (number of consecutive stents, total stent length, stent length in lesions stented with a single stent, stent length in lesions stented with multiple stents, stent diameter), duration of the follow-up since stent implantation.

    Measured: through study completion, average of 1 year

  2. To compare radiation exposure of third-generation dual-source CCTA to ICA, measured as effective dose, in patients receiving both examinations.

    Radiation exposure of third-generation dual-source CCTA (dose length product (DLP), milligray*cm) and radiation exposure of ICA (dose area product (DAP), gray*cm2) were converted to effective dose (millisievert, mSv) and compared.

    Measured: from CCTA to possible ICA, up two 7.3 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted9 Aug 2024
  2. Study start16 Jan 2023
  3. Primary completion10 Nov 2023
  4. Study completion8 Jun 2024

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Diagnosis
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
45 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06543641
Sponsor's protocol ID
M1016TUTLA
Status last verified
Aug 2024
First submitted
25 Jul 2024
Last updated
9 Aug 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Mansikkaniemi L, Stewart JA, Sinisalo J, Laine P, Holmstrom M. Third-generation computed tomography angiography after coronary chronic total occlusion intervention in ruling out significant in-stent restenosis at long-term follow-up. Scand Cardiovasc J. 2025 Dec;59(1):2550280. doi: 10.1080/14017431.2025.2550280. Epub 2025 Sep 2.

    PubMed 40832939

Questions about this trial

What is this clinical trial studying?

A study testing Coronary computed tomography angiography and Invasive coronary angiography in people with Coronary Artery Disease and Chronic Total Occlusion of Coronary Artery, run by Lauri Mansikkaniemi at 1 site in Finland.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 9 Aug 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Finland. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Stent patency assesment with third-generation dual-source CCTA (time frame: up to 7.3 months (maximum time between CCTA and ICA)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06543641, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Aug 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in